Unlocking the potential of solute carrier (SLC) transporters against incurable diseases

From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD., Ph.D., formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.


JPH203, a small molecule that targets biliary tract cancer, is currently in Phase IIb trials with results expected in 2Q 2022. In the U.S., we are targeting breakthrough designation in 1Q 2023 and FDA approval in 4Q 2026. Another small molecule LAT-1 inhibitor, OKY034, is being developed for autoimmune disease with a US IND expected in 4Q 2022.

Masuhiro Yoshitake
President & CEO
Hitoshi Endou
MD., Ph D.,
Voice from Acceralator

Initiate oncology clinical study by 2Q 2023, and initiate multiple sclerosis clinical study by 4Q 2023 in the US J-Pharma is a clinical stage biotechnology company focused on SLC transporters. JPH-203 is a small molecular currently being investigated in a pivotal registration clinical study for patients with advanced, refractory biliary tract cancer in Japan. J-Pharma will have Topline results in 2nd Quarter 2022 and plan to initiate a clinical study of JPH203 for the same indication in the US by organizing an end-of-phase 2 meeting with the FDA. Also collaborating with leading academic institutions to prioritize and conduct basic research on the immunological indications of LAT1. J-Pharma is proceeding with preclinical and IND-enabling studies for OKY034 in MS and plan to initiate a clinical study by 4Q 2023 in the US.